JeffreyMichaelKamradtMD

PubMed

• 15 citations
  Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial Carcinoma.
  Jonathan A Coleman, Wesley Yip, Nathan C Wong, Daniel D Sjoberg, Bernard H Bochner, Guido Dalbagni, S Machele Donat, Harry W Herr, Eugene K Cha, Timothy F Donahue, Eug...> ;Journal of Clinical Oncology. 2023 Mar 10
• 25 citations
  Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial.
  Samuel A Funt, Michael Lattanzi, Karissa Whiting, Hikmat Al-Ahmadie, Colleen Quinlan, Min Yuen Teo, Chung-Han Lee, David Aggen, Danielle Zimmerman, Deaglan McHugh, Arl...> ;Journal of Clinical Oncology. 2022 Apr 20
• 94 citations
  Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline
  Edouard J. Trabulsi, R. Bryan Rumble, Hossein Jadvar, Thomas A. Hope, Martin G. Pomper, Baris Turkbey, Andrew B. Rosenkrantz, Sadhna Verma, Daniel Margolis, Adam T. Fr...> ;Journal of Clinical Oncology. 2020 Jan 15
• 58 citations
  Suppression of tumor recurrence and metastasis by a combination of the PHSCN sequence and the antiangiogenic compound tetrathiomolybdate in prostate carcinoma.
  Kenneth L. van Golen, Liwei Bao, George J. Brewer, Kenneth J. Pienta, Jeffrey M. Kamradt, Donna L. Livant, Sofia D. Merajver> ;Neoplasia. 2002 Jan 1
• 30 citations
  Treatment of androgen-independent prostate cancer using antimicrotubule agents docetaxel and estramustine in combination: an experimental study.
  Jeffrey F. Williams, Heather J. Muenchen, Jeffrey M. Kamradt, Susan Korenchuk, Kenneth J. Pienta> ;The Prostate. 2000 Sep 1
• 10 citations
  Etoposide in prostate cancer.
  Jeffrey M. Kamradt, Kenneth J. Pienta> ;Expert Opinion on Pharmacotherapy. 2000 Jan 1
• 12 citations
  Signaling network of paclitaxel-induced apoptosis in the LNCaP prostate cancer cell line☆
  Ravat Panvichian, Kim Orth, Mary Josephine P. Pilat, Mark L. Day, Kathleen C. Day, Christina S.K. Yee, Jeffrey M. Kamradt, Kenneth J. Pienta> ;Urology. 1999 Oct 1
• 3 citations
  Oral chemotherapy for hormone refractory prostate cancer. The University of Michigan experience.
  Jeffrey M. Kamradt, David Smith, Kenneth J. Pienta> ;The Urologic Clinics of North America. 1999 May 1
• Rational use of chemotherapy. It is not just rat poison.
  Jeffrey M. Kamradt, Eric A. Klein, Kenneth J. Pienta> ;The Urologic Clinics of North America. 1999 May 1
• 6 citations
  Novel molecular targets for prostate cancer therapy.
  Jeffrey M. Kamradt, Kenneth J. Pienta> ;Seminars in Oncology. 1999 Apr 1
• 1 citations
  Oral chemotherapy in the treatment of hormone-refractory prostate cancer
  Kenneth J. Pienta, Jeffrey M. Kamradt, David Smith> ;Drugs. 1999 Jan 1
• 3 citations
  Carboplatin-induced cell death in model prostate cancer systems.
  Christina S.K. Yee, Jeffrey M. Kamradt, L C Nielsen, R Panvinchian, Kenneth J. Pienta> ;Anticancer Research. 1998 Nov 1
• 1 citations
  The effect of hydrazine sulfate on prostate cancer growth
  Jeffrey M. Kamradt, Kenneth J. Pienta> ;Oncology Reports. 1998 Jul 1
• Join now to see all